A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS) in Combination With TAK-536 in Subjects With Type II Diabetes.

Trial Profile

A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS) in Combination With TAK-536 in Subjects With Type II Diabetes.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs Azilsartan; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Takeda Global Research and Development Center
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Jan 2009 Planned patient number added (704) as reported by ClinicalTrials.gov.
    • 17 Oct 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top